Peripheral nerves are links between the brain and the spinal cord along with the rest of human’s body. Peripheral nerves are highly fragile and can be easily damaged. Peripheral nerve injuries/lesions might be mild or severe. Sometimes a peripheral lesion caused either the fiber injury or insulation is damaged. These type of peripheral lesion are more likely to heal with medications. However, in case of more-severe peripheral nerve injuries/ peripheral lesions both the fibers as well as the insulation is damaged. Such peripheral lesions are difficult to treat and patient may not completely recover from peripheral nerve injury. Early diagnosis of peripheral lesions and proper treatment in many of the cases could help prevent complications and permanent nerve injury. Peripheral lesions are registered to be partial if some sort of sensory function or residual motor is observed in distribution of injured nerve segment. It is recommended that incomplete peripheral lesions/ nerve injuries should be treated conservatively. However, complete nerve lesions/ peripheral lesions caused by penetrating injuries are referred for early surgical examination followed by direct end-to-end repair. A number of patients having peripheral lesions develop neuropathic pain in addition to sensory and motor deficits from the nerve injury. For symptomatic control of neuropathic pain escalating drug regimen are used. Long-acting nonsteroidal anti-inflammatory drugs (NSAIDs) are used to effectively treat patients with mild pain.
The increasing approval for novel pain management drugs mainly nonsteroidal anti-inflammatory drugs (NSAIDs) by the FDA worldwide is projected to drive peripheral lesions treatment market revenue growth over the forecast years. However, patients with severe neuropathic pain who are unresponsive to NSAIDs might need narcotic analgesia for treatment of severe pain caused due to peripheral lesions. The increase in product commercialization and FDA approval activities for oxycodone and analgesics for peripheral nerve injuries by leading manufacturers. With the increasing rise in development of peripheral lesions treatment therapies, the number of drugs due for FDA approval or under development is expected to increase, thus proving to be the prominent driving factor for the growth of peripheral lesions treatment market.
The global peripheral lesions treatment market is segmented on basis of treatment type, form, distribution channel and geographic region:
Segmentation by Treatment Type
Segmentation by Form
Segmentation by Distribution Channel
The peripheral lesions treatment market is categorized based on product type, form and end user. Based on product type, the peripheral lesions treatment are classified into two major drug classes including Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Anti-Inflammation Agents, Opioids, Narcotic Analgesics, Antiepileptic Drug (AED) and others. Among these peripheral lesions treatment drugs, NSAIDs are the most preferred peripheral lesions treatment drug type. On the basis of form, injectable segment is expected to expand its growth at a substantial CAGR over the forecast years. Hospitals and ASCs followed by hospital pharmacies and retail pharmacies is expected to register significant revenue growth during the forecast period.
North America and Europe together are projected to maintain their dominance and register substantial market revenue share in global peripheral lesions treatment market due to increased patient pool for peripheral nerve injuries in the regions. The launch of new peripheral lesions treatment drugs and escalating surgical procedures in the U.S. market enables North America to seize substantial revenue share in peripheral lesions treatment market. Asian countries are entirely focused on production of new peripheral lesions treatment therapeutics at low prices thereby assisting South Asian and East Asian countries to achieve revenue growth at a high CAGR over forecast period.
Some of the major key manufacturers involved in global peripheral lesions treatment market are AstraZeneca plc, Novartis, Sanofi, Pfizer, Teva Pharmaceuticals, GlaxoSmithKline plc, and others.
The report covers exhaustive analysis on:
Regional analysis includes